Reykjavikurvegur 78 - 80
+354 420 6700
Coripharma is a European generic pharmaceutical company, built on solid heritage. The company’s experienced team offers contract manufacturing and out-licensing services to pharmaceutical companies that demand the highest quality and service from a reliable European supplier
Located in Iceland, inside Schengen and the European Economic Area (EEA), Coripharma’s manufacturing site was initially established in 1981 for local pharmaceutical production. In 1998 the facility was expanded with a 7,000 m2 factory and 900 m2 finished goods warehouse. With regular launches on day one, often as the first company to market after patents expired in Europe, the manufacturing site played an essential role in the growth story of Actavis.
Coripharma specializes in pharmaceutical contract manufacturing; solid oral dosage forms, conventional and controlled generic pharmaceutical products.
Coripharma offers its clients:
The company’s manufacturing site in Hafnarfjordur, Iceland, has an annual production capacity of about 1.2 billion tablets/capsules.
Coripharma’s manufacturing site is equipped with machinery for standard mixing, granulation, tableting, film-coating and packaging.
Two granulation suites equipped with high-shear mixers and fluidized bed drying equipment (300 and 600 L capacity), offering batch sizes of up to 2 million tablets.
Coripharma‘s manufacturing site, a zero-carbon footprint facility, holds a GMP license for the European Union (EU). The facilities have also been successfully inspected by authorities in other major markets.
Coripharma offers out-licensing and supply of generic pharmaceuticals, developed in house, including analytical development, regulatory- and IP support to other pharmaceutical companies.
The company’s focus is on solid oral dose products; IR, tablets & capsules and ER tablets (DR & PR). Coripharma is also capable of developing powder/granule sachets and effervescent products.
Coripharma has an established development process, ranging from formulation to dossier completion and submission.
The Hafnarfjordur, Iceland site was taken over by Teva Pharmaceuticals in 2016, as part of its global acquisition of Actavis’ generics business. A group of former Actavis/Teva employees and local investors acquired the site from Teva in 2018. A year later Coripharma also purchased the former Actavis R&D site, located at the same premises.
Since then, Coripharma has further strengthened its team of highly experienced and reputable industry experts and executives. The company now successfully offers out-licensing of its own developed products and contract manufacturing to pharmaceutical companies in markets around the world.